7. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71:1121-1128.
8. Harrison N, Brydon L, Walker C, Gray M, Steptoe A, Critchley H. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biological Psychiatry. 2009;66:407-414.
9. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology. 2016;16:22-34.
10. Anders S, Tanaka M, Kinney DK. Depression as an evolutionary strategy for defense against infection. Brain, Behavior, and Immunity. 2013;31:9-22.
11. Watson JD, Crick FH. Molecular structure of nucleic acids. Nature. 1953;171:737-738.
12. Clinton WJ. The Human Genome Project. 2000; https://www.youtube.com/watch?v=slRyGLmt3qc.
13. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88-109.
14. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychological Bulletin. 2014;140:774-815.
15. Danese A, Moffitt TE, Harrington H, et al. Adverse childhood experiences and adult risk factors for age-related disease: Depression, inflammation and clustering of metabolic risk markers. Archives of Pediatric and Adolescent Medicine. 2009;163:1135-1143.
Chapter 2
16. MacPherson G, Austyn J. Exploring Immunology: Concepts and evidence. Germany: Wiley-Blackwell; 2012.
Chapter 3
17. National Rheumatoid Arthritis Society. Invisible disease: rheumatoid arthritis and chronic fatigue. London; 2014.
18. Lokhorst G-J. Descartes and the pineal gland. The Stanford Enyclopedia of Philosophy 2016; https://plato.stanford.edu/archives/sum2016/entries/pineal-gland/.
19. Descartes R. Treatise of Man. Harvard University Press; 1637.
20. Depression Alliance. Twice as likely: putting long term conditions and depression on the agenda. London; 2012.
21. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews Immunology. 2002;2:364-371.
22. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. The Lancet. 1994;344:1105-1110.
23. Hess A, Axmann R, Rech J, et al. Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system. Proceedings of the National Academy of Scientists USA. 2011;108:3731-3736.
Chapter 4
24. Telles-Correia D, Marques JG. Melancholia before the twentieth century: fear and sorrow or partial insanity? Frontiers in Psychology. 2015;6.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition ed. Arlington: American Psychiatric Publishing; 2013.
26. Auden WH. In memory of Sigmund Freud. Another Time. London: Random House; 1940.
27. Freud S. An autobiographical study. In: Strachey J, ed. Standard Edition of the Complete Psychological Works of Sigmund Freud. Vol 20. London: Hogarth Press; 1927, 1959:1-74.
28. Masson JM. The Assault on Truth. New York: Farrar Straus Giroux; 1984.
29. Freud S. Project for a scientific psychology. In: Strachey J, ed. Standard Edition of the Complete Psychological Works of Sigmund Freud. Vol 1. London: Hogarth Press; 1895, 1950.
30. Wampold BE, Mondin GW, Moody M, Stich F, Benson K, Ahn H-N. A meta-analysis of outcome studies comparing bona fide psychotherapies: empirically, “all must have prizes”. Psychololgical Bulletin. 1997;122:203-215.
31. Molière. Le malade imaginaire. London: Methuen; 1981.
32. Lòpez-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of anti-depressants from 1950s until today. Current Pharmaceutical Design. 2009;15:1563-1586.
33. Kline NS. Iproniziad for the treatment of severe depression. Albert Lasker Clinical Medical Research Award Citations 1964; http://www.laskerfoundation.org/awards/show/iproniazid-for-the-treatment-of-severe-depression/.
34. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. American Journal of Psychiatry. 1965;122:509-522.
35. Wong DT, Perry KW, Bymaster FP. The discovery of fluoxetine hydrochloride (Prozac). Nature Reviews Drug Discovery. 2005;4:764-774.
36. Wurtzel E. Prozac Nation: Young and Depressed in America. Vancouver: Penguin; 1994.
37. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012;380:1829-1839.
38. Bentley B, Branicky R, Barnes CL, et al. The multilayer connectome of Caenorhabditis elegans. PLoS Computational Biology. 2016;12:p.e1005283.
39. Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Molecular Psychiatry. 2012;17:1174-1179.
40. Cavanagh J, Patterson J, Pimlott S, et al. Serotonin transporter residual availability during long-term antidepressant therapy does not differentiate responder and nonresponder unipolar patients. Biological Psychiatry. 2006;59:301-308.
Chapter 5
41. Dantzer R, Kelley KW. Stress and immunity: an integrated view of relationships between the brain and the immune system. Life Sciences. 1989;44:1995-2008.
42. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimaki M. Cumulative meta-analysis of interleukins 6 and 1-beta, tumour necrosis factor-alpha and C-reactive protein in patients with major depressive disorder. Brain, Behavior, and Immunity. 2015;49:206-215.
43. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biological Psychiatry. 2010;67:446-457.
44. Wium-Andersen MK, Orsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. JAMA Psychiatry. 2013;70:176-184.
45. Bell JA, Kivimaki M, Bullmore ET, Steptoe A, Carvalho LA, Consortium MI. Repeated exposure to systemic inflammation and risk of new depressive symptoms among older adults. Translational Psychiatry. 2017;7:p.e1208.
46. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant alphainterferon in hepatitis B carriers. The Lancet. 1987;330:1175-1178.
47. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-a and ribavirin treatment. Molecular Psychiatry. 2009;14:1095-1104.
48. Conan Doyle A. A Study in Scarlet. Ware: Wordsworth Press; 1887, 2001.
49. Willans G, Searle R. Down with Skool! London: Methuen; 1953.
50. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337-341.
51. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends in Immunology. 2007;28:12-18.
52. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859.
53. Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences. 2016;113:8284-8289.
54. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of baseline activation and neural response data. American Journal of Psychiatry. 2012;169:693-703.
55. Phan KL, Wager T, Taylor SF, Liberzon I. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. NeuroImage. 2002;16:331-348.
56. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in m
ajor depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Archives of General Psychiatry. 2004;61:877-889.
57. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity. 2007;21:153-160.
58. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nature Reviews Neurology. 2014;10:217-224.
59. Morris GP, Clark IA, Zinn R, Vissel B. Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiology of Learning and Memory. 2013;105:40-53.
60. Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-a: relationship to CNS immune responses and depression. Molecular Psychiatry. 2010;15:393-403.
61. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853-858.
Chapter 6
62. Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953-966.
63. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of General Psychiatry. 2010;67:220-229.
64. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Research Reviews. 2009;8:18-30.
65. Dopico XC, Evangelou M, Ferreira RC, et al. Widespread seasonal gene expression reveals annual differences in human immunity and physiology. Nature Communications. 2015;6:7000.
66. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women. American Journal of Psychiatry. 2000;157:1243-1251.
67. Mazure CM. Life stressors as risk factors in depression. Clinical Psychology: Science and Practice. 1998;5:291-313.
68. Kendler KS, Hettema JM, Butera F, Gardner CO, Prescott CA. Life event dimensions of loss, humiliation, entrapment and danger in the prediction of onsets of major depression and generalized anxiety. Archives of General Psychiatry. 2003;60:789-796.
69. Boyle PJ, Feng Z, Raab GM. Does widowhood increase mortality risk? Testing for selection effects by comparing causes of spousal death. Epidemiology. 2011;22:1-5.
70. Carey IM, Shah SM, DeWilde S, Harris T, Victor CR, Cook DG. Increased risk of acute cardiovascular events after partner bereavement: a matched cohort study. JAMA Internal Medicine. 2014;174:598-605.
71. Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nature Reviews Neuroscience. 2016;17:497-511.
72. Reader BF, Jarrett BL, McKim DB, Wohleb ES, Godbout JP, Sheridan JF. Peripheral and central effects of repeated social defeat stress: monocyte trafficking, microglial activation, and anxiety. Neuroscience. 2015;289:429-442.
73. Schultze-Florey CR, Martínez-Maza O, Magpantay L, et al. When grief makes you sick: Bereavement induced systemic inflammation is a question of genotype. Brain, Behavior, and Immunity. 2012;26:1066-1071.
74. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nature Reviews Immunology. 2005;5:243-251.
75. Bellingrath S, Rohleder N, Kudielka BM. Effort-reward-imbalance in healthy teachers is associated with higher LPS-stimulated production and lower glucocorticoid sensitivity of interleukin-6 in vitro. Biological Psychology. 2013;92:403-409.
76. Kiecolt-Glaser JK, Derry HM, Fagundes CP. Inflammation: depression fans the flames and feasts on the heat. American Journal of Psychiatry. 2015;172:1075-1091.
77. Cohen IV, Makunts T, Atayee R, Abagyan R. Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Scientific Reports. 2017;7:1450.
78. Darwin C, Prodger P. The Expression of the Emotions in Man and Animals. USA: Oxford University Press; 1998.
79. Psychiatric Genetics Consortium. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorder. bioRxiv. 2017.
80. Liu W, Yan M, Liu Y, et al. Olfactomedin 4 down-regulates innate immunity against Helicobacter pylori infection. Proceedings of the National Academy of Sciences. 2010;107:11056-11061.
Chapter 7
81. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. The Journal of Clinical Endocrinology & Metabolism. 2009;94:1104-1110.
82. Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS ONE. 2011;6:p.e19590.
83. Nordentoft M, Wahlbeck K, Hallgren J, et al. Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS ONE. 2013;8:p.e55176.
84. Miller G. Is pharma running out of brainy ideas? Science. 2010;329:502-504.
85. Arrowsmith J, Harrison R. Drug repositioning: the business case and current strategies to repurpose shelved candidates and marketed drugs. In: Barratt MJ, Frail DE, eds. Drug repositioning: Bringing new life to shelved assets and existing drugs. Hoboken, NJ: John Wiley & Sons, Inc.; 2012:9-31.
86. Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381-1391.
87. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Molecular Psychiatry. 2016.
88. Wittenberg G, Stylianou A, Zhang Y, et al. A mega-analysis of immunomodulatory drug effects on depressive symptoms. bioRxiv. 2018.
89. Raison CL, Rutherford RE, Wollwin BJ, et al. A randomised controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory markers. JAMA Psychiatry. 2013;70:31-41.
90. Groves DA, Brown VJ. Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neuroscience and Biobehavioral Reviews. 2005;29:493-500.
91. Fox D. The electric cure. Nature. 2017;545:20-22.
92. Creswell JD, Irwin MR, Burklund LJ, et al. Mindfulness-based stress reduction training reduces loneliness and pro-inflammatory gene expression in older adults: a small randomized controlled trial. Brain, Behavior, and Immunity. 2012;26:1095-1101.
93. Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: a descriptive review. Brain, Behavior, and Immunity. 2016;51:1-11.
94. Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. The Lancet. 1997;349:1546-1549.
95. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. The International Journal of Biochemistry & Cell Biology. 2005;37:289-305.
96. McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Annals of the New York Academy of Sciences. 2004;1035:104-116.
97. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. New England Journal of Medicine. 2013;368:117-127.
98. Kraepelin E, Diefendorf AR. Clinical psychiatry: a text-book for students and physicians. London: Macmillan; 1915.
99. Noll R. Kraepelin’s “lost biological psychiatry”? Auto-intoxication, organotherapy and surgery for dementa praecox. History of Psychiatry. 2007;18:301-320.
100. Psychiatric Genetics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421-427.
101. Sekar A, Bialas AR, de Rivera H, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177-183.
102. Davies G
, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophrenia Bulletin. 2003;29:587-593.
103. Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. The Lancet Psychiatry. 2015;2:258-270.
104. Zandi MS, Irani SR, Lang B, et al. Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology. 2011;258:686-688.
Index
A note about the index: The pages referenced in this index refer to the page numbers in the print edition. Clicking on a page number will take you to the ebook location that corresponds to the beginning of that page in the print edition. For a comprehensive list of locations of any word or phrase, use your reading system’s search function.
acute inflammation 22, 24
adenoids 35
adipose tissue 148
adrenaline 95, 99, 99–100, 101, 105, 153
African plains 167
aging 148–9
alcoholism 164, 179
alderman’s itch 130–1
Alzheimer, Alois 207–8, 209
Alzheimer’s disease 152, 173, 178, 208–9
anti-inflammatory treatments 209–10
biomarkers 212
clinical trials for drugs 210
discovery of 208
genes 212
global disorder 211
injecting fragments of amyloid 211
panaceas 212
personalised immune treatments for 213
American Psychiatric Association 147
amino acids 17
amygdala 134, 135
amyloid proteins 209
anatomy 48
ancestral savannah 166–74, 175 see also genes
anhedonia 72
animal life 49, 137–8
animals
Descarte’s views on 137
inflammation and 144
The Inflamed Mind Page 20